ClearOne is trading 5% down today at $7.00 after investors reacted negatively to the approved reverse-merger with Cortigent and its heavy dilution impact for existing shareholders.
- The company plans to pivot from AV/collaboration hardware into neurostimulation med-tech following the deal.
- Vivani Medical is expected to own a majority stake in the new entity, leaving current ClearOne holders with a significantly smaller slice of the combined business.